Literature DB >> 8636345

Novel mutations in the estrogen receptor messenger RNA in human breast cancers.

L C Murphy1, M Wang, A Coutt, H Dotzlaw.   

Abstract

One mechanism that has been suggested to play a role in the progression of human breast cancer from hormone dependence to independence is the expression or altered expression of mutant and/or variant forms of estrogen receptor (ER). Two major types of variant ER messenger (m)RNA have been identified in human breast biopsy samples so far: truncated transcripts and exon deleted transcripts. In this study we provide data indicating the existence of a novel type of abnormal ER mRNA. These transcripts were identified as larger than wild-type ER mRNA RT-PCR products in 9.4% of 212 human breast tumors analyzed. The data suggest nucleotide insertions are present in ER mRNA of some breast tumors. Cloning and sequencing of the larger RT-PCR products showed three different types: a complete duplication of exon 6 occurring in 7.5% of tumors; a complete duplication of both exons 3 and 4 occurring in 1 tumor; and a 69 nucleotide insertion between exons 5 and 6 occurring in 3 tumors. Open reading frame analysis suggested that exon 6 duplicated transcripts encoded a 51.4 kDa ER-like protein truncated just after exon 6 sequences; the exon 3 and 4 duplicated transcript encoded a 83.3 kDa protein containing duplication of ER amino acid residues encoded by exons 3 and 4; the 69 nucleotide insertion was inframe, adding 23 novel amino acid residues between residues 412 and 413 of the normal ER protein to produce a 68.8 kDa protein. It is unknown if these novel ER-like mRNAs are stably translated in vivo. Any resulting protein would be structurally altered, however, possibly resulting in altered function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636345     DOI: 10.1210/jcem.81.4.8636345

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Expression of estrogen receptor variant messenger RNAs and determination of estrogen receptor status in human breast cancer.

Authors:  A Huang; E R Leygue; L Snell; L C Murphy; P H Watson
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Regulation of transcriptional activation function of rat estrogen receptor α (ERα) by novel C-terminal splice inserts.

Authors:  Pallob Kundu; Min Li; Rong Lu; Enrico Stefani; Ligia Toro
Journal:  Mol Cell Endocrinol       Date:  2014-11-07       Impact factor: 4.102

Review 3.  Estrogen receptor variants.

Authors:  T A Hopp; S A Fuqua
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

4.  POU transcription factors Brn-3a and Brn-3b interact with the estrogen receptor and differentially regulate transcriptional activity via an estrogen response element.

Authors:  V Budhram-Mahadeo; M Parker; D S Latchman
Journal:  Mol Cell Biol       Date:  1998-02       Impact factor: 4.272

5.  Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele.

Authors:  K Juottonen; M Lehtovirta; S Helisalmi; P J Riekkinen; H Soininen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

6.  Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions.

Authors:  Brian J Miller; Daolong Wang; Ralf Krahe; Fred A Wright
Journal:  Am J Hum Genet       Date:  2003-09-16       Impact factor: 11.025

7.  Immunodetection of nmt55/p54nrb isoforms in human breast cancer.

Authors:  M Pavao; Y H Huang; L J Hafer; R B Moreland; A M Traish
Journal:  BMC Cancer       Date:  2001-10-29       Impact factor: 4.430

8.  Development and characterization of a tamoxifen-resistant breast carcinoma xenograft.

Authors:  H Naundorf; M Becker; A E Lykkesfeldt; B Elbe; C Neumann; B Büttner; I Fichtner
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.